Reproducibility and Effect of Levodopa on Dopamine Transporter Function Measurements: A [18F]CFT PET Study
Open Access
- 1 November 2000
- journal article
- clinical trial
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 20 (11) , 1604-1609
- https://doi.org/10.1097/00004647-200011000-00010
Abstract
The objective of this article was to study the reproducibility and effect of levodopa on dopamine transporter function measurements using 2β-carbomethoxy-3β-(4-[18F]-fluorophenyl)tropane ([18F]CFT) positron emission tomography (PET). Seven de novo patients with Parkinson's disease (PD) were studied twice, before and after three months of levodopa medication. Eight healthy volunteer subjects participated in the reproducibility study. The [18F]CFT PET scan was done twice with an interval of approximately 2.5 months. The regions of interest (anterior and posterior putamen, caudate nucleus, and cerebellum) were drawn on individual magnetic resonance imaging (MRI) images, matched with the PET images, and copied onto the PET images. The [18F]CFT uptake was calculated as the region–cerebellum:cerebellum ratio at 180 to 210 minutes. Three-month levodopa treatment in PD patients had no significant effect on [18F]CFT uptake in any striatal subregion between the two PET scans. In PD patients, the percent change from baseline was 4.1% in the anterior putamen, 1.9% in the posterior putamen, and 4.0% in the caudate nucleus. No significant differences in [18F]CFT uptake between the first and second PET scan in any striatal subregion occurred in healthy controls. The intraclass correlation, indicating the reproducibility of the PET scan within subjects, was 0.94 for the anterior putamen, 0.86 for the posterior putamen, and 0.91 for the caudate nucleus. The percent change from baseline was 4.0% in the anterior putamen, 1.1% in the posterior putamen, and 2.8% in the caudate nucleus. Long-term levodopa treatment in PD patients had no effect on the [18F]CFT uptake in the striatum and the test–retest reproducibility was very high. These findings confirm [18F]CFT as a suitable ligand to monitor progression of PD.Keywords
This publication has 17 references indexed in Scilit:
- Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [18F]CFTAnnals of Neurology, 2000
- Effect of treatment withL-dopa/carbidopa orL-selegiline on striatal dopamine transporter SPECT imaging with [123I]?-CITMovement Disorders, 1999
- [18F]CFT ([18F]WIN 35,428), a radioligand to study the dopamine transporter with PET: Characterization in human subjectsSynapse, 1998
- Change in lateralization of the P22/N30 cortical component of median nerve somatosensory evoked potentials in patients with cervical dystonia after successful treatment with botulinum toxin AMovement Disorders, 1998
- [ 18 F]CFT ([ 18 F]WIN 35,428), a radioligand to study the dopamine transporter with PET: Biodistribution in ratsSynapse, 1996
- Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease.Proceedings of the National Academy of Sciences, 1993
- SPECT imaging of dopamine and serotonin transporters with [123I]β‐CIT: Pharmacological characterization of brain uptake in nonhuman primatesSynapse, 1993
- A Clinicopathologic Study of 100 Cases of Parkinson's DiseaseArchives of Neurology, 1993
- Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsyAnnals of Neurology, 1990
- Determination of plasma [18F]-6-fluorodopa during positron emission tomography: Elimination and metabolism in carbidopa treated subjectsLife Sciences, 1986